🇺🇸 FDA
Pipeline program

Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

20453A

Phase 1 other active

Quick answer

Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease for Active, moderate-to-severe TED is a Phase 1 program (other) at H. Lundbeck A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
H. Lundbeck A/S
Indication
Active, moderate-to-severe TED
Phase
Phase 1
Modality
other
Status
active

Clinical trials